These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 1983798)

  • 1. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+:neopterin ratio correlates with p24 antigenaemia in HIV infected patients.
    Crocchiolo PR; Lizioli A; Cantaluppi P; Filippi C; D'Agostino F; Cambié G; Panzeri MP; Nardella ML
    J Clin Lab Immunol; 1990 Feb; 31(2):55-7. PubMed ID: 1983767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate markers for AIDS treatment.
    Jacobson M
    Nurs Times; 1991 May 29-Jun 4; 87(22):49. PubMed ID: 1675013
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users.
    Rezza G; Titti F; Pezzotti P; Sernicola L; Lo Caputo S; Angarano G; Lazzarin A; Sinicco A; Rossi GB; Verani P
    J Biol Regul Homeost Agents; 1992; 6(1):15-20. PubMed ID: 1359736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
    Siller L; Martin NL; Kostuchenko P; Beckett L; Rautonen J; Cheng SC; Wara DW
    AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lymphocyte subpopulations, neopterin, and beta-2-microglobulin: relationship with clinical stage, risk of progression to AIDS and presence of active infection in HIV infection].
    Antón F; Labarga P; Pinilla J; Soto MJ; Leoz A; del Cura J; Borque L; Milazzo A
    Enferm Infecc Microbiol Clin; 1993; 11(7):373-7. PubMed ID: 8104488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].
    Halota W; Jaruga B; Pawłowska M
    Pol Merkur Lekarski; 2002 Aug; 13(74):126-8. PubMed ID: 12420343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open trial of tacrine therapy in 70 HIV-infected patients.
    Fredj G; Dietlin F; Jasmin C; Maurisson G; Barbier M; Bayce P; Ratiney R; Rudant E; Debat P; Kalifa D
    Int J Clin Pharmacol Ther Toxicol; 1992 Sep; 30(9):313-6. PubMed ID: 1358832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum IgD behaviour in HIV-1 infected patients.
    Raiteri R; Albonico M; Deiana R; Marietti G; Sinicco A
    Allergol Immunopathol (Madr); 1991; 19(1):6-10. PubMed ID: 1950942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
    Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
    Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The natural history and laboratory parameters of HIV infection].
    Brühwiler J; Lüthy R; Joller-Jemelka HI; Ledergerber B; Fierz W; Siegenthaler W; Grob PJ
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1015-20. PubMed ID: 2500318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
    Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
    Chaisson RE; Leuther MD; Allain JP; Nusinoff-Lehrman S; Boone GS; Feigal D; Volberding P
    Arch Intern Med; 1988 Oct; 148(10):2151-3. PubMed ID: 3263098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
    Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
    Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-2-microglobulin, neopterin and monocyte Fc gamma receptors in opportunistic infections of HIV-positive patients.
    Dunne J; Feighery C; Whelan A
    Br J Biomed Sci; 1996 Dec; 53(4):263-9. PubMed ID: 9069103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.